Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 5/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | AOC2 | O75106 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | VCP | P55072 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10130720 | 0.82 | AOC2 (0.37) | PIK3CDP2RX7AOC2L3MBTL1ALDH1A1 | |
| SCHEMBL21740018 | 0.81 | AOC2 (0.36) | PIK3CDAOC2L3MBTL1ALDH1A1GAA | |
| SCHEMBL24300045 | 0.79 | AOC2 (0.36) | PIK3CDP2RX7POLBAOC2NPC1 | |
| SCHEMBL10250697 | 0.79 | TSHR (0.50) | PIK3CDP2RX7AOC2PRMT5WDR77 | |
| SCHEMBL2619229 | 0.78 | PIK3CD (0.55) | PIK3CDP2RX7POLBHDAC1NPC1 | |
| SCHEMBL18926693 | 0.78 | PIK3CD (0.67) | PIK3CDP2RX7POLBNPC1RAB9A | |
| SCHEMBL29344874 | 0.78 | AOC2 (0.37) | PIK3CDAOC2VCP | |
| SCHEMBL26790474 | 0.77 | PIK3CD (0.36) | PIK3CD | |
| SCHEMBL22012732 | 0.77 | PIK3CD (0.56) | PIK3CDP2RX7POLBHDAC1L3MBTL1 | |
| SCHEMBL13290566 | 0.77 | PIK3CD (0.56) | PIK3CDP2RX7POLBHDAC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | PIK3CD 3272/4885P2RX7 3197/4885POLB 692/4885 |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | PIK3CD 3272/4885P2RX7 3197/4885POLB 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.